Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”)

Documenti analoghi

• Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
  di: Fradet, Y, et al.
  Pubblicazione: (2019)
• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
  di: Bellmunt, J., et al.
  Pubblicazione: (2017)
• Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
  di: Nishiyama, Hiroyuki, et al.
  Pubblicazione: (2019)
• Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
  di: Chen, Robert, et al.
  Pubblicazione: (2019)
• A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)()()()
  di: Si, Lu, et al.
  Pubblicazione: (2019)